Financial Performance - CalciMedica reported a net loss of 13.7millionfortheyearendedDecember31,2024,asignificantimprovementfromanetlossof34.4 million in 2023[11]. - Total operating expenses decreased to 24,204millionin2024from38,075 million in 2023, a reduction of approximately 36.4%[18]. - Net loss improved to 13,700millionin2024comparedtoanetlossof34,357 million in 2023, representing a reduction of about 60.1%[18]. - Net loss per share decreased to 1.22in2024from7.66 in 2023, indicating a significant improvement in per-share performance[18]. - Overall, the financial performance indicates a positive trend with significant reductions in losses and operating expenses year-over-year[18]. Expenses - Research and development expenses decreased to 14.5millionin2024from15.9 million in 2023, primarily due to a reduction in personnel expenses related to a merger[11]. - General and administrative expenses were 9.7millionin2024,downfrom22.2 million in 2023, reflecting a decrease in personnel expenses driven by one-time charges from the merger[11]. - Research and development expenses were 14,478millionin2024,downfrom15,859 million in 2023, reflecting a decrease of about 8.7%[18]. - General and administrative expenses significantly decreased to 9,726millionin2024from22,216 million in 2023, a decline of approximately 56.3%[18]. - The company reported a loss from operations of 24,204millionin2024,downfrom38,075 million in 2023, a decrease of about 36.4%[18]. Assets and Funding - Cash, cash equivalents, and short-term investments totaled 18.7millionasofDecember31,2024,expectedtofundoperationsintomid−2026[11].−Thetotalassetsincreasedto19.8 million as of December 31, 2024, compared to 12.2millionin2023[16].−Thecompanysecuredacreditfacilityofupto32.5 million to support its operations, with an initial tranche of 10millionalreadyfunded[10].ClinicalTrialsandDevelopment−EnrollmentisongoinginthePhase2KOURAGEtrial,targeting150patientswithsevereacutekidneyinjuryandassociatedrespiratoryfailure,withdataexpectedbytheendof2025[4].−Apost−hocanalysisfromthePhase2CARDEAtrialindicateda62.710,504 million in 2024, up from 3,718millionin2023,markinganincreaseofabout182.59,490 million in 2024 from $3,168 million in 2023, a growth of approximately 199.2%[18]. Shareholder Information - Weighted-average number of shares outstanding increased to 11,245,915 in 2024 from 4,486,258 in 2023, reflecting an increase of approximately 150.1%[18].
